Cargando…
Oncologic Outcome after Cessation or Dose Reduction of Capecitabine in Patients with Colon Cancer
PURPOSE: Oral capecitabine has been used as adjuvant therapy for colorectal cancer patients since the 1990s. Patient-initiated cessation or reduced use of capecitabine occurs widely for various reasons, yet the consequences of these actions are unclear. The present study sought to clarify treatment...
Autores principales: | Yun, Jung-A, Kim, Hee Cheol, Son, Hyun-Sook, Kim, Hyoung Ran, Yun, Hae Ran, Cho, Yong Beom, Yun, Seong Hyeon, Lee, Woo Yong, Chun, Ho-Kyung |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Coloproctology
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2998011/ https://www.ncbi.nlm.nih.gov/pubmed/21152231 http://dx.doi.org/10.3393/jksc.2010.26.4.287 |
Ejemplares similares
-
Compliance and Effective Management of the Hand-Foot Syndrome in Colon Cancer Patients Receiving Capecitabine as Adjuvant Chemotherapy
por: Son, Hyun-Sook, et al.
Publicado: (2009) -
Oncologic Outcomes of Stage IIIA Colon Cancer for Different Chemotherapeutic Regimens
por: Lee, Yoo Sung, et al.
Publicado: (2012) -
Cessation or dose reduction of Capecitabine due to Complications in Patients with Colon Cancer
por: Sohn, Seung Kook
Publicado: (2010) -
Treatment Outcomes of Anorectal Melanoma
por: Choi, Byung Min, et al.
Publicado: (2011) -
Transanal Endoscopic Microsurgery for the Treatment of Well-Differentiated Rectal Neuroendocrine Tumors
por: Kim, Hyoung Ran, et al.
Publicado: (2012)